The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.

Silzle, Tobias; Blum, Sabine; Kasprzak, Annika; Nachtkamp, Kathrin; Rudelius, Martina; Hildebrandt, Barbara; Götze, Katharina S; Gattermann, Norbert; Lauseker, Michael; Germing, Ulrich

doi:10.3390/cancers15143572

2023

Zurück
Zurück zum Anfang der Trefferliste
Dauerhafter Link zum angezeigten Objekt

Titel:: The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Dokumenttyp:: Article; Journal Article
Autor(en):: Silzle, Tobias; Blum, Sabine; Kasprzak, Annika; Nachtkamp, Kathrin; Rudelius, Martina; Hildebrandt, Barbara; Götze, Katharina S; Gattermann, Norbert; Lauseker, Michael; Germing, Ulrich
Abstract:: The absolute monocyte count (AMC) is associated with mortality in a variety of medical conditions. Its prognostic impact in myelodysplastic syndromes (MDSs) is less well studied. Therefore, we investigated its potential prognostic value in a cohort from the Düsseldorf MDS registry in relationship to the revised international prognostic scoring system (IPSS-R). An AMC below the population's median (<0.2 × 109/L) was associated with several adverse disease features such as lower haemoglobin levels, lower count of neutrophils and platelets, and a higher percentage of blasts in the bone marrow. MDS patients with an AMC < 0.2 × 109/L had a significantly higher risk of progression into acute myeloid leukemia (AML). In a univariate, proportional hazards model the effect of the AMC as a continuous variable was modelled via p-splines. We found a U-shaped effect with the lowest hazard around 0.3 × 109/L. Accordingly, an AMC within the last quartile of the population (0.4 × 109/L) was associated with a reduced overall survival independently of IPSS-R, but not with the risk of secondary AML. Considering monocytopenia as a risk factor for AML progression in MDS may provide an additional argument for allogeneic transplantation or the use of hypomethylating agents in patients who are not clear candidates for those treatments according to current prognostic scoring systems and/or recommendations. Further studies are needed to assess the prognostic impact of the AMC in the context of prognostic scoring systems, considering the molecular risk profile, and to identify the mechanisms responsible for the higher mortality in MDS patients with a subtle monocytosis.
Zeitschriftentitel:: Cancers (Basel)
Jahr:: 2023
Band / Volume:: 15
Heft / Issue:: 14
Volltext / DOI:: doi:10.3390/cancers15143572
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/37509235
TUM Einrichtung:: Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)2023